Synactix Pharmaceuticals, Inc.

Synactix is a biotechnology start-up specializing in the development of small-molecule "single agent pharmacology" therapies for human disease treatment. Synactix has licensed a cancer treatment based on novel compound capable of blocking multiple signaling proteins responsible for tumor growth which treats medullary thyroid cancer and shows further positive indications.
Hong Yu Li
Brendan Frett
Massimo Santoro
Francesca Carlomagno
College of Pharmacy